Baricitinib delays the progression of type 1 diabetes
In a world-first, ATIC researchers lead by Professor’s Thomas Kay and Helen Thomas have shown that baricitinib, an immunotherapy treatment commonly used in rheumatoid arthritis, can delay the progression of type 1 diabetes and preserve the body’s ability to make its own insulin.
What does ATIC do?
ATIC is working across six distinct interconnected Domains to ensure maximum impact and fulfil our bold vision.
Clinical trials
Drive the implementation of immunotherapy clinical trials throughout Australia and New Zealand
Community engagement
Work closely with the type 1 diabetes community across the research cycle, from trial development through recruitment to communication of...
Data management
Harmonise data collection and ensure linkage with national and international diabetes networks.
Education and training
Train, equip and update clinicians, scientists and the wider community on the fundamentals of immunotherapy, as well as the latest...
Preclinical and translation
Attract immunotherapy trials to Australasia through innovation: the discovery of improved biomarkers, development of new therapies, and facilitation of biosample...
Regulation and government
Advocate for regulatory approval and government funding of immunotherapy treatments for type 1 diabetes.
T1D RELAY - Rituximab-pvvr and Abatacept Newly Diagnosed Study
ATIC is conducting the TrialNet lead T1D RELAY trial in Melbourne at The Royal Melbourne Hospital. T1D RELAY is available for people ages 8-45 years who have been diagnosed with type 1 diabetes in the last three months.
Care pathways for people with early-stage type 1 diabetes in Australia
July 2024
A group of ATIC clinician-researchers with support from JDRFA have published the Australian guidelines “Care pathways for people with early-stage type 1 diabetes in Australia”, concurrently with the publication of international consensus guidelines.
Making a National Screening Program for Type 1 Diabetes a Reality in Australia: Progress and Plans
July 2024
Seminar 18, Beyond Insulin Seminar Series – Dr Kirstine Bell presents ‘Making a National Screening Program for Type 1 Diabetes a Reality in Australia: Progress and Plans’
Clinical translation of antigen-specific immunotherapy for type 1 diabetes – from discovery to clinical trials
June 2024
Seminar 17, Beyond Insulin Seminar Series – Professor Ranjeny Thomas talk about ‘clinical translation of antigen-specific immunotherapy for type 1 diabetes’.
Measuring what matters: psychosocial and behavioural outcomes in T1D trials
May 2024
Seminar 16, Beyond Insulin Seminar Series – Dr Elizabeth Holmes-Truscott present ‘Measuring what matters: the assessment of psychosocial and behavioural outcomes in type 1 diabetes trials’.
We partner with global leaders in our field
Supported by
Coordinating Centre
